Pluristyx, Inc., with expertise in gene-edited induced pluripotent stem cells (iPSCs) and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines today, today announced a collaboration agreement to streamline the transition of promising iPSC-derived therapies from the benchtop to the bedside.
The partnership provides a pathway to transition early-stage iPSC reprogramming, gene editing, development, and banking performed at Pluristyx to Resilience for late-stage GMP operations and drug product manufacturing. Working together, this partnership provides a streamlined workflow for clients to generate clinical grade iPSCs and then transfer that starting material to Resilience for downstream operations. This agreement further provides Resilience clients to access Pluristyx’s proprietary FailSafe® safety switch and iACT Stealth CellsTM cloaking technologies and custom modifications to create universal donor clinical-grade master cell banks applicable for regulatory filings.
“Navigating the maze of outside resources to develop the next generation of cell-based therapies is challenging for many early-stage groups. By partnering with Resilience, Pluristyx offers a straightforward pathway to generate best-in-class iPSC starting materials that can be easily transferred to Resilience for clinical manufacturing, dramatically decreasing the time and complexity associated with cell therapy product development,” states Benjamin Fryer, PhD, Chief Executive Officer at Pluristyx.
About Resilience
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell/ gene therapy modalities and drug product). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit https://resilience.com